Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-early tranexamic acid after subarachnoid hemorrhage
NL-OMON46921Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tranexamic acid in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Favorable functional outcome at 6 months. Started Jul 2013; status: active, not recruiting.
02
Drugs
tranexamic acid
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON46921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46921.